Faron Pharmaceuticals Oy Stock Return On Equity
| FARN Stock | 170.00 2.50 1.49% |
Faron Pharmaceuticals Oy fundamentals help investors to digest information that contributes to Faron Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Faron Stock. The fundamental analysis module provides a way to measure Faron Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Faron Pharmaceuticals stock.
Faron | Return On Equity |
Faron Pharmaceuticals Oy Company Return On Equity Analysis
Faron Pharmaceuticals' Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Faron Pharmaceuticals Return On Equity | -39.61 |
Most of Faron Pharmaceuticals' fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Faron Pharmaceuticals Oy is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Faron Total Stockholder Equity
Total Stockholder Equity |
|
Based on the latest financial disclosure, Faron Pharmaceuticals Oy has a Return On Equity of -39.615. This is much lower than that of the Biotechnology sector and significantly lower than that of the Health Care industry. The return on equity for all United Kingdom stocks is notably higher than that of the company.
Faron Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Faron Pharmaceuticals' direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Faron Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Faron Pharmaceuticals by comparing valuation metrics of similar companies.Faron Pharmaceuticals is currently under evaluation in return on equity category among its peers.
Faron Fundamentals
| Return On Equity | -39.61 | ||||
| Return On Asset | -0.7 | ||||
| Current Valuation | 163.6 M | ||||
| Shares Outstanding | 104.62 M | ||||
| Shares Owned By Insiders | 31.81 % | ||||
| Shares Owned By Institutions | 10.35 % | ||||
| Price To Book | 156.09 X | ||||
| Price To Sales | 16.21 X | ||||
| Gross Profit | 803 K | ||||
| EBITDA | (28.37 M) | ||||
| Net Income | (30.94 M) | ||||
| Total Debt | 13.11 M | ||||
| Book Value Per Share | 0.01 X | ||||
| Cash Flow From Operations | (23.81 M) | ||||
| Earnings Per Share | (0.31) X | ||||
| Target Price | 1009.02 | ||||
| Number Of Employees | 34 | ||||
| Beta | 0.33 | ||||
| Market Capitalization | 177.86 M | ||||
| Total Asset | 10.22 M | ||||
| Retained Earnings | (172.21 M) | ||||
| Working Capital | (6.14 M) | ||||
| Net Asset | 10.22 M |
About Faron Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Faron Pharmaceuticals Oy's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Faron Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Faron Pharmaceuticals Oy based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Faron Stock Analysis
When running Faron Pharmaceuticals' price analysis, check to measure Faron Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Faron Pharmaceuticals is operating at the current time. Most of Faron Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Faron Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Faron Pharmaceuticals' price. Additionally, you may evaluate how the addition of Faron Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.